GNRX

VanEck Vectors Generic Drugs ETF
CLOSING PRICECHANGE (%)VOLUME
$22.75-- (--)1
4:00:00 p.m. (ET) 06/23/2017
PRE-MARKET SESSION
LAST TRADECHANGE (%)
---- (--)
BID SIZEBID ($)ASK ($)ASK SIZE
--------
N/A

N/A
  • Overview
  • Efficiency
  • Tradability
  • Fit

GNRX Fund Description

The VanEck Vectors Generic Drugs ETF is composed of U.S. and international companies that have a primary business focus on the generic drug industry.

GNRX FactSet Analytics Insight

GNRX is the first ETF to focus specifically on generic drug manufacturers. With more people than ever taking prescription drugs across the globe, the generic drug industry is expected to grow strongly as it provides a lower cost alternative to brand name pharmaceuticals. GNRX’s market cap weighted portfolio is comprised of companies that currently derive or have the potential to derive a significant portion of their revenues from the generic drug industry. The fund casts a wide net to include firms across the size spectrum from both developed and emerging market countries. With respect to fees, GNRX is a little bit pricey but not out of line with similar niche funds.
GNRX’s specific investment thesis is likely to cause a poor fit to our broader pharmaceuticals benchmark. A low Fit score however, should not be considered a negative as it is entirely consistent with the fund’s objective.

GNRX MSCI ESG Fund metrics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of June 26, 2017 the VanEck Vectors Generic Drugs ETF MSCI ESG Fund Quality Score is 3.86 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. GNRX ranks in the 4th percentile within its peer group and in the 6th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:

GNRX Top 10 Countries View All

GNRX Top 10 Sectors

GNRX Top 10 Holdings View All

GNRX Summary Data

01/12/16
Open-Ended Fund
0.55%
$3.44 M
$21.47 K
0.76%

GNRX Portfolio Data

$12.56 B
41.17
2.49
0.42%
12/18/17
40

GNRX Index Data

Indxx Global Generics & New Pharma Index
Market Cap
Committee
Thomson Reuters Global Pharmaceuticals

Related ETFs to GNRX

PPH
Total Return
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max

GNRX Portfolio Management

0.55%
--
--
--

GNRX Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

GNRX Fund Structure

Open-Ended Fund
No
Yes
100% / 0%
N/A
N/A
High
Daily
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
------
------
------
------
------
------
------
------
------
------
Bats BZX Real-time Quote - 08:08:39
Average Spread
Premium/Discount
Volume

GNRX FactSet Analytics Block Liquidity

As of 06/27/17
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of GNRX. GNRX is rated a 1 out of 5.

GNRX Tradability

745
$21.47 K
360
$11.64 K
0.76%
$0.17
0.33%
3.50% / -1.84%
None
46.00%
50,000
0.01
0.04%
0.95%
--
$22.75
1

GNRX Performance Statistics

0.56
0.94
0.88
1.10
0.55%
Thomson Reuters Global Pharmaceuticals

GNRX MSCI ESG Fund Metrics

3.86 / 10
4.14
6.31
3.16%
10.13%
61.70